Novel immunotherapies for T cell lymphoma and leukemia
P Ghione, AJ Moskowitz, NEK De Paola… - Current hematologic …, 2018 - Springer
Current hematologic malignancy reports, 2018•Springer
Abstract Purpose of Review Novel immunotherapies such as checkpoint inhibitors, bispecific
antibodies, and chimeric antigen receptor T cells are leading to promising responses when
treating solid tumors and hematological malignancies. T cell neoplasms include leukemia
and lymphomas that are derived from T cells and overall are characterized by poor clinical
outcomes. This review describes the rational and preliminary results of immunotherapy for
patients with T cell lymphoma and leukemia. Recent Findings For T cell neoplasms, despite …
antibodies, and chimeric antigen receptor T cells are leading to promising responses when
treating solid tumors and hematological malignancies. T cell neoplasms include leukemia
and lymphomas that are derived from T cells and overall are characterized by poor clinical
outcomes. This review describes the rational and preliminary results of immunotherapy for
patients with T cell lymphoma and leukemia. Recent Findings For T cell neoplasms, despite …
Purpose of Review
Novel immunotherapies such as checkpoint inhibitors, bispecific antibodies, and chimeric antigen receptor T cells are leading to promising responses when treating solid tumors and hematological malignancies. T cell neoplasms include leukemia and lymphomas that are derived from T cells and overall are characterized by poor clinical outcomes. This review describes the rational and preliminary results of immunotherapy for patients with T cell lymphoma and leukemia.
Recent Findings
For T cell neoplasms, despite significant research effort, only few agents, such as monoclonal antibodies and allogeneic stem cell transplantation, showed some clinical activity. One of the major hurdles to targeting T cell neoplasms is that activation or elimination of T cells, either normal or neoplastic, can cause significant toxicity. A need to develop novel safe and effective immunotherapies for T cell neoplasms exists.
Summary
In this review, we will discuss the rationale for immunotherapy of T cell leukemia and lymphoma and present the most recent therapeutic approaches.
Springer
